AstraZeneca's new ADC targeting CD123 approved for clinical trials in China.
I'm PortAI, I can summarize articles.
AstraZeneca's new ADC drug, AZD9829, has been granted clinical trial implicit approval in China for the treatment of CD123-positive hematologic malignancies. The drug has demonstrated strong killing ability against AML cells in vitro and exhibited anti-tumor activity in 13 AML patient models. AstraZeneca is also conducting clinical studies in the United States to evaluate the drug's safety and preliminary anti-tumor activity. The implicit approval for clinical trials obtained this time will pave the way for the drug's clinical research in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments